Acquisitions (Schedule Of Valuation Of The Intangible Assets Acquired And Related Amortization Periods) (Details) - Par Pharmaceutical Holdings, Inc. $ in Millions	Sep. 25, 2015 USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	$ 3,472.5
In-process research and development
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	1,456.7
In-process research and development | IPR&D 2019 Launch
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	401.0
In-process research and development | IPR&D 2018 Launch
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	283.8
In-process research and development | Ezetimibe
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	147.6
In-process research and development | IPR&D 2016 Launch
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	133.3
In-process research and development | Ephedrine Sulphate
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	128.6
In-process research and development | Neostigmine vial
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	118.6
In-process research and development | Other IPR&D
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	243.8
Developed Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	2,015.8
Developed Technology | Vasostrict®
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	$ 556.0
Amortization period	8 years
Developed Technology | Aplisol®
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	$ 312.4
Amortization period	11 years
Developed Technology | Developed - Other - Non-Partnered (Generic Non-Injectable)
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	$ 230.4
Amortization period	7 years
Developed Technology | Developed - Other - Partnered (Combined)
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	$ 164.4
Amortization period	7 years
Developed Technology | Nascobal®
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	$ 118.3
Amortization period	9 years
Developed Technology | Developed - Other - Non-Partnered (Generic Injectable)
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	$ 116.4
Amortization period	10 years
Developed Technology | Other Developed Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation	$ 517.9
Amortization period	9 years